Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and PK of ATTO1310 in Adult Volunteers, Patients With Atopic Dermatitis, and Patients With Chronic Pruritus
Sponsor: Attovia Therapeutics Inc
Listed as NCT06787586, this PHASE1 trial focuses on Atopic Dermatitis (AD) and Atopic Eczema and remains ongoing. Sponsored by Attovia Therapeutics Inc, it has been updated 7 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2025 — Mar 2026 [monthly]
Recruiting PHASE1
-
Oct 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
Aug 2025 — Oct 2025 [monthly]
Recruiting PHASE1
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Feb 2025 — Apr 2025 [monthly]
Recruiting PHASE1
First recorded
Jan 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Attovia Therapeutics Inc
For direct contact, visit the study record on ClinicalTrials.gov .